Home › NDC Lookup › RxCUI directory › RxCUI 630939

1 ML hyaluronidase, human recombinant 150 UNT/ML Injection [Hylenex] — RxCUI 630939

Name: 1 ML hyaluronidase, human recombinant 150 UNT/ML Injection [Hylenex] (RxCUI 630939)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 630939 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI630939

Official name1 ML hyaluronidase, human recombinant 150 UNT/ML Injection [Hylenex]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asHylenex 150 UNT per 1 ML Injection; Hylenex 150 UNT in 1 ML Injection

FDA products mapped2

Package NDCs mapped2

Reported Medicaid activity (SDUD)696 prescriptions · 10 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

🕸️ Concept Web — How 1 ML hyaluronidase, human recombinant 150 UNT/ML... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 1 ML hyaluronidase, human recombinant 150 UNT/ML Injection [Hylenex] RxCUI 630939 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Hyaluronidase 5464 IN
- Hyaluronidase, human recombinant 1300478 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Hylenex 615870 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Hyaluronidase Injection 1809548 SCDF
- Hyaluronidase, human recombinant Injection 2649077 SCDFP
- Hyaluronidase Injectable Product 1161541 SCDG
- Hyaluronidase, human recombinant Injectable Product 2660415 SCDGP
- Hyaluronidase Injection [Hylenex] 1809565 SBDF
- Hyaluronidase, human recombinant Injection [Hylenex] 2656186 SBDFP
- Hylenex Injectable Product 1176106 SBDG
- Injection 1649574 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 1 ML hyaluronidase, human recombinant 150 UNT/ML Injection 630936 SCD
- Hyaluronidase, human recombinant 150 UNT/ML 1809562 SCDC
- Hyaluronidase, human recombinant 150 UNT/ML [Hylenex] 1809564 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

1 ML hyaluronidase, human recombinant 150 UNT/ML Injection SCD · 630936
Hyaluronidase, human recombinant 150 UNT/ML SCDC · 1809562
Hyaluronidase Injection SCDF · 1809548
Hyaluronidase, human recombinant Injection SCDFP · 2649077
Hyaluronidase Injectable Product SCDG · 1161541
Hyaluronidase, human recombinant Injectable Product SCDGP · 2660415

Brand-Name Concepts

Hyaluronidase, human recombinant 150 UNT/ML [Hylenex] SBDC · 1809564
Hyaluronidase Injection [Hylenex] SBDF · 1809565
Hyaluronidase, human recombinant Injection [Hylenex] SBDFP · 2656186
Hylenex Injectable Product SBDG · 1176106
Hylenex BN · 615870

📦 FDA Products & Package NDCs

2 products · 2 package NDCs

2 package NDCs map to RxCUI 630939 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
18657-0117-04	4 BOX in 1 CARTON (18657-117-04) / 1 VIAL in 1 BOX (18657-1...	HYLENEX Recombinant	Antares Pharma, Inc.	2005-12-02
51662-1555-01	1 VIAL in 1 BOX (51662-1555-1) / 1 mL in 1 VIAL	HYALURONIDASE	HF Acquisition Co LLC, DBA HealthFirst	2021-06-04

Observed labelers: Antares Pharma, Inc. (1) · HF Acquisition Co LLC, DBA HealthFirst (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per ml · median

$53.6656

Range $53.6656–$53.6656 · middle 50% $53.6656–$53.6656 · 1 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J3473	Hyaluronidase recombinant	2	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.